Cancer research luminary Bert Vogelstein is adding to his line of cancer diagnostic companies, following Exact Sciences, Inostics, PGDx and Thrive (which was bought by Exact).

Haystack Oncology is launching out of Catalio Capital Management, where Vogelstein serves as a venture partner as well. It’s starting out with a $56 million Series A, adding to its $10 million in seed funding, which was led by Catalio but also featured research tool manufacturer Bruker, the venture arm of Exact, and Alexandria Venture Investments.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

CG Oncology is cashing in on its interim data update.

Tuesday morning, the Irvine, CA-based biotech announced that it raised $120 million — eclipsing the combined $87 million it’s brought in since its inception 12 years ago. The raise comes after CG posted updated data at SITC for its oncolytic virus candidate in combination with Keytruda for non-muscle invasive bladder cancer, or NMIBC, in patients who did not respond to standard Bacillus Calmette-Guérin (BCG) therapy.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

John Mulligan was in the process of raising about $90 million for a Series B to take Good Therapeutics’ PD-1-regulated IL-2 into the clinic when the board decided to do a smaller round while fielding buyout talks from Big Pharma companies.

He ended up selling the company — or more specifically, that lead program and the underlying intellectual property — to Roche for $250 million upfront, plus a slate of biobucks, and returning the money to investors. But the 26 employees, lab lease and the technology for making conditionally active cancer drugs remained, in the form of a new company named Bonum Therapeutics, which was sustained by a bridge round of $3 million.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Whatever Roche has learned about Jnana Therapeutics’ drug discovery platform over the past two years, it’s intrigued enough to set up a second partnership.

While the last deal had centered on solute carriers — or SLCs, the huge family of proteins that Jnana had built its name on — this time around, Roche wants to apply Jnana’s tech on a range of other hard-to-drug targets. The pharma giant will dish out $50 million upfront, plus “significant near-term milestone payments” and more than $2 billion in milestones.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

In the summer of 2020, a successful scientist/investor team took the wraps off their latest project in MBX Biosciences. But at the time, they left most granular details up to the imagination.

On Monday, MBX revealed what it’s been working on and how it plans to move forward.

The biotech, helmed by CEO Kent Hawryluk and his longtime business partner and CSO Richard DiMarchi, closed a $115 million Series B round Monday, led by Wellington Management. RA Capital — the Peter Kolchinsky/Rajeev Shah-led firm with a knack for steering quick Nasdaq leaps — also chipped in.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Lipidio Pharmaceuticals launched right before Covid-19 took the world by storm, initially focusing on metabolic indications such as NASH, Prader-Willi Syndrome and anti-psychotic drug-induced weight gain.

More than 2.5 years later, the biotech has added dermatology to that list and secured some of the industry’s most well-known investors for a Series A extension round.

Lipidio announced on Thursday morning that it has raised more than $20 million. It also secured three former biotech chiefs as new investors: Tanox founder and ex-CEO Nancy Chang, Allergan veteran Brent Saunders and founding Alnylam CEO John Maraganore, who seems to be everywhere these days after leaving his post at the RNAi giant.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN